IART (Integra LifeSciences Holdings)
Insider Trading Activity
Every open-market purchase and sale reported by IART officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-04 | Chantal Veillon-Berteloot | EVP & CHRO | F | — | — |
| 2026-07-06 | ROBERT T. DAVIS JR. | EVP & President, TR&DT | A | — | — |
| 2026-07-06 | Jeffrey Mosebrook | SVP, Fin & Princ Acct Officer | F | — | — |
| 2026-07-06 | Harvinder Singh | EVP & President, SS | A | — | — |
| 2026-07-06 | Lea Daniels Knight | EVP & Chief Financial Officer | F | — | — |
| 2026-06-03 | STUART ESSIG | President and CEO | A | — | — |
| 2026-06-03 | Michael J. McBreen | EVP & Chief Commercial Officer | A | — | — |
| 2026-05-11 | Renee Wonlai Lo | Director | A | — | — |
| 2026-05-11 | Shaundra Clay | Director | A | — | — |
| 2026-05-11 | KEITH BRADLEY | Director | F | — | — |
| 2026-05-11 | CHRISTIAN S SCHADE | Director | A | — | — |
| 2026-05-11 | JEFFREY A GRAVES | Director | A | — | — |
| 2026-05-11 | BARBARA B HILL | Director | A | — | — |
| 2026-03-12 | Michael Damon Hutchinson | EVP, Chief Legal Officer & Sec | A | — | — |
| 2026-03-12 | Lea Daniels Knight | EVP & Chief Financial Officer | F | — | — |
| 2026-03-12 | Chantal Veillon-Berteloot | EVP & CHRO | F | — | — |
| 2026-03-12 | Mojdeh Poul | President & CEO | A | — | — |
| 2026-03-12 | ROBERT T. DAVIS JR. | EVP & President, TT | F | — | — |
| 2026-03-12 | Jeffrey Mosebrook | SVP, Fin & Princ Acct Officer | F | — | — |
| 2026-03-12 | Harvinder Singh | EVP & PRESIDENT, INTERNATIONAL | MIXED | — | — |
| 2026-03-12 | Michael J. McBreen | EVP & President, CSS | F | — | — |
| 2026-02-04 | Michael Damon Hutchinson | EVP, Chief Legal Officer & Sec | A | — | — |
| 2026-01-07 | Mojdeh Poul | President & CEO | MIXED | — | — |
| 2025-11-06 | JEFFREY A GRAVES | Director | Buy | — | — |
| 2025-10-14 | Harvinder Singh | EVP & PRESIDENT, INTERNATIONAL | MIXED | — | — |
| 2025-09-02 | Chantal Veillon-Berteloot | EVP & CHRO | F | — | — |
| 2025-08-18 | STUART ESSIG | Director | J | — | — |
| 2025-07-07 | Lea Daniels Knight | EVP & Chief Financial Officer | F | — | — |
| 2025-07-07 | Jeffrey Mosebrook | SVP, Fin & Princ Acct Officer | F | — | — |
| 2025-07-02 | Jeffrey Mosebrook | SVP, Fin & Princ Acct Officer | F | — | — |
| 2025-05-13 | Shaundra Clay | Director | A | — | — |
| 2025-05-13 | JEFFREY A GRAVES | Director | A | — | — |
| 2025-05-13 | CHRISTIAN S SCHADE | Director | A | — | — |
| 2025-05-13 | BARBARA B HILL | Director | A | — | — |
| 2025-05-13 | KEITH BRADLEY | Director | MIXED | — | — |
| 2025-05-13 | Renee Wonlai Lo | Director | A | — | — |
| 2025-05-13 | STUART ESSIG | Exec. Chairman of the Board | A | — | — |
| 2025-03-13 | Jeffrey Mosebrook | SVP, Fin & Princ Acct Officer | MIXED | — | — |
| 2025-03-13 | Harvinder Singh | EVP & PRESIDENT, INTERNATIONAL | MIXED | — | — |
| 2025-03-13 | ROBERT T. DAVIS JR. | EVP & President, TT | MIXED | — | — |
| 2025-03-13 | Lea Daniels Knight | EVP & CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2025-03-13 | Chantal Veillon-Berteloot | EVP & CHRO | MIXED | — | — |
| 2025-03-13 | Michael J. McBreen | EVP & President, CSS | MIXED | — | — |
| 2025-03-13 | Eric Schwartz | EVP, Chief Legal Officer & Sec | F | — | — |
| 2025-03-11 | Harvinder Singh | EVP & PRESIDENT, INTERNATIONAL | MIXED | — | — |
| 2025-03-11 | Jeffrey Mosebrook | SVP, Fin & Princ Acct Officer | F | — | — |
| 2025-03-11 | Eric Schwartz | EVP, Chief Legal Officer & Sec | F | — | — |
| 2025-03-11 | ROBERT T. DAVIS JR. | EVP & President, TT | F | — | — |
| 2025-03-11 | Michael J. McBreen | EVP & President, CSS | F | — | — |
| 2025-01-08 | Mojdeh Poul | President & CEO | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 10,454,873 | — |
| — | 10%+ Owner | 8,515,930 | — |
| — | President and CEO | 1,152,236 | — |
| — | President & CEO | 263,318 | — |
| — | Director | 169,841 | — |
| — | Director | 90,034 | — |
| — | Director | 88,254 | — |
| — | Director | 82,768 | — |
| — | EVP & President, TR&DT | 74,874 | — |
| — | Corp VP, Pres. Adv Woundcare | 68,960 | — |
| — | CorpVP, CAO | 68,318 | — |
| — | Director | 62,569 | — |
| — | EVP & Chief Commercial Officer | 60,743 | — |
| — | Executive Vice President & CFO | 57,811 | — |
| — | EVP, Chief Legal Officer & Sec | 56,020 | — |
| — | Director | 55,753 | — |
| — | Director | 45,454 | — |
| — | EVP & Chief Financial Officer | 45,263 | — |
| — | Director | 44,638 | — |
| — | CVP,PRES - CODMAN SPC SURGICAL | 42,673 | — |
| — | Director | 41,515 | — |
| — | Director | 41,086 | — |
| — | Director | 35,743 | — |
| — | Executive Vice President & COO | 34,622 | — |
| — | SVP, Fin & Princ Acct Officer | 34,516 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IART quote page; the site-wide leaderboard is on the insider transactions hub.